guest ::
| Home > Publications database > Circulating Isovalerylcarnitine and Lung Cancer Risk: Evidence from Mendelian Randomization and Pre-Diagnostic Blood Measurements. > print |
| Home > Publications database > Circulating Isovalerylcarnitine and Lung Cancer Risk: Evidence from Mendelian Randomization and Pre-Diagnostic Blood Measurements. > print |
| 001 | 180700 | ||
| 005 | 20240229145629.0 | ||
| 024 | 7 | _ | |a 10.1158/1055-9965.EPI-21-1033 |2 doi |
| 024 | 7 | _ | |a pmid:35839461 |2 pmid |
| 024 | 7 | _ | |a 1055-9965 |2 ISSN |
| 024 | 7 | _ | |a 1538-7755 |2 ISSN |
| 024 | 7 | _ | |a altmetric:132607280 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-01496 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Smith-Byrne, Karl |0 0000-0002-1932-7463 |b 0 |
| 245 | _ | _ | |a Circulating Isovalerylcarnitine and Lung Cancer Risk: Evidence from Mendelian Randomization and Pre-Diagnostic Blood Measurements. |
| 260 | _ | _ | |a Philadelphia, Pa. |c 2022 |b AACR |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1665143237_4150 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2022 Oct 4;31(10):1966-1974 |
| 520 | _ | _ | |a Tobacco exposure causes 8 of 10 lung cancers, and identifying additional risk factors is challenging due to confounding introduced by smoking in traditional observational studies.We used Mendelian randomization (MR) to screen 207 metabolites for their role in lung cancer predisposition using independent genome-wide-association studies (GWAS) of blood metabolite levels (n =7,824) and lung cancer risk (n=29,266 cases / 56,450 controls). A nested case control study (656 cases and 1,309 matched controls) was subsequently performed using pre-diagnostic blood samples to validate MR association with lung cancer incidence data from population-based cohorts (EPIC and NSHDS).An MR-based scan of 207 circulating metabolites for lung cancer risk identified that blood isovalerylcarnitine (IVC) was associated with a decreased odds of lung cancer after accounting for multiple testing (Log10-OR = 0.43, 95% CI: 0.29-0.63). Molar measurement of IVC in pre-diagnostic blood found similar results (Log10-OR = 0.39, 95% CI: 0.21-0.72). Results were consistent across lung cancer sub-types.Independent lines of evidence support an inverse association of elevated circulating IVC with lung cancer risk through a novel methodological approach that integrates genetic and traditional epidemiology to efficiently identify novel cancer biomarkers.Our results find compelling evidence in favor of a protective role for a circulating metabolite, IVC, in lung cancer aetiology. From the treatment of a Mendelian disease, isovaleric acidemia, we know that circulating IVC is modifiable through a restricted protein diet or glycine and L-carnatine supplementation. IVC may represent a modifiable and inversely associated biomarker for lung cancer. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Cerani, Agustin |0 0000-0002-9633-7796 |b 1 |
| 700 | 1 | _ | |a Guida, Florence |0 0000-0002-9652-2430 |b 2 |
| 700 | 1 | _ | |a Zhou, Sirui |0 0000-0003-4963-0815 |b 3 |
| 700 | 1 | _ | |a Agudo, Antonio |0 0000-0001-9900-5677 |b 4 |
| 700 | 1 | _ | |a Aleksandrova, Krasimira |0 0000-0002-1275-1827 |b 5 |
| 700 | 1 | _ | |a Barricarte, Aurelio |0 0000-0001-6750-1270 |b 6 |
| 700 | 1 | _ | |a Rodríguez-Barranco, Miguel |0 0000-0002-9972-9779 |b 7 |
| 700 | 1 | _ | |a Borchers, Christoph H |0 0000-0003-2394-6512 |b 8 |
| 700 | 1 | _ | |a Gram, Inger T |0 0000-0002-0031-4152 |b 9 |
| 700 | 1 | _ | |a Han, Jun |0 0000-0002-9477-8782 |b 10 |
| 700 | 1 | _ | |a Amos, Christopher I |0 0000-0002-8540-7023 |b 11 |
| 700 | 1 | _ | |a Hung, Rayjean J |0 0000-0002-4486-7496 |b 12 |
| 700 | 1 | _ | |a Grankvist, Kjell |0 0000-0003-4289-2097 |b 13 |
| 700 | 1 | _ | |a Nøst, Therese H |0 0000-0001-6805-3094 |b 14 |
| 700 | 1 | _ | |a Imaz, Liher |0 0000-0002-3777-4953 |b 15 |
| 700 | 1 | _ | |a Chirlaque-López, María Dolores |0 0000-0001-9242-3040 |b 16 |
| 700 | 1 | _ | |a Johansson, Mikael |0 0000-0003-4182-8923 |b 17 |
| 700 | 1 | _ | |a Kaaks, Rudolf |0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |b 18 |u dkfz |
| 700 | 1 | _ | |a Kühn, Tilman |0 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe |b 19 |
| 700 | 1 | _ | |a Martin, Richard M |0 0000-0002-7992-7719 |b 20 |
| 700 | 1 | _ | |a McKay, James D |0 0000-0002-1787-3874 |b 21 |
| 700 | 1 | _ | |a Pala, Valeria |0 0000-0001-5438-970X |b 22 |
| 700 | 1 | _ | |a Robbins, Hilary A |0 0000-0001-6041-6866 |b 23 |
| 700 | 1 | _ | |a Sandanger, Torkjel M |0 0000-0002-4062-872X |b 24 |
| 700 | 1 | _ | |a Schibli, David |0 0000-0001-8249-8188 |b 25 |
| 700 | 1 | _ | |a Schulze, Matthias B |0 0000-0002-0830-5277 |b 26 |
| 700 | 1 | _ | |a Travis, Ruth C |0 0000-0002-9571-0763 |b 27 |
| 700 | 1 | _ | |a Vineis, Paolo |0 0000-0001-8935-4566 |b 28 |
| 700 | 1 | _ | |a Weiderpass, Elisabete |0 0000-0003-2237-0128 |b 29 |
| 700 | 1 | _ | |a Brennan, Paul |0 0000-0002-0518-8714 |b 30 |
| 700 | 1 | _ | |a Johansson, Mattias |0 0000-0002-3116-5081 |b 31 |
| 700 | 1 | _ | |a Richards, J Brent |0 0000-0002-3746-9086 |b 32 |
| 773 | _ | _ | |a 10.1158/1055-9965.EPI-21-1033 |g p. EPI-21-1033 |0 PERI:(DE-600)2036781-8 |n 10 |p 1966-1974 |t Cancer epidemiology, biomarkers & prevention |v 31 |y 2022 |x 1055-9965 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:180700 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 18 |6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 19 |6 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-02-02 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-10 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCER EPIDEM BIOMAR : 2021 |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-10 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2022-11-10 |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|